Rani Therapeutics Inc (RANI) - Forward P/S Multiple
Rani Therapeutics (RANI) is developing a revolutionary robotic pill to replace biologic injections. High growth potential is driven by licensing this unique technology to major industry players in exchange for royalties. However, geopolitics complicates patent protection and raw material logistics. The business's forward P/S reflects market expectations, with the latest value recorded as 9.30, helping to assess the risk of asset undervaluation.
Comprehensive metric breakdowns and analytics for Rani Therapeutics Inc (RANI)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Rani Therapeutics|RANI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Rani Therapeutics Holdings, Inc.|RANI - Company Cumulative Indebtedness|Debts to Book Capitalization Rani Therapeutics Holdings|RANI - Company Long-Term Loans and Borrowings|Company Short-Term Debts Rani Therapeutics|Quick Liquidity ranitherapeutics.com
- business earnings and investment ratios data:
RANI - Final Profit|Projected Future Earnings Rani Therapeutics|RANI - P/E Multiple|Future Price to Earnings Rani Therapeutics Holdings|RANI - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple RANI|RANI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Rani Therapeutics|RANI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ranitherapeutics.com|RANI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Rani Therapeutics
- sales and revenue indicators:
General company analysis:Rani Therapeutics Holdings, Inc. RANI
Minimizing fundamental risks requires an analysis of the forward P/S ratio, which compares current market capitalization with expected revenue to assess the premium paid for future cash flows. For Rani Therapeutics (RANI), this indicator reflects the market value of its patent monopoly on robotic biologic delivery, allowing the forward P/S ratio to evaluate the capitalization potential of its technological advantage over major pharmaceutical behemoths.
Key competitors
Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP
